In 2023, Stanley C. Erck earned $4.01M in total compensation at Novavax, including $50.90K salary and $129.78K in stock. Most recently sold 47,689 shares in Sep 2024. Currently holds stock worth $1.26M. Has led Novavax for over 14 years.
Compensation History
Annual executive compensation data for Stanley C. Erck, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$4.01M
Salary
$50.90K
Bonus
$0.00
Other
$3.83M
Salary
$50.90KBoard Justification
The compensation philosophy is designed to attract and retain highly qualified executives while aligning their interests with those of stockholders through performance-based incentives.
Bonus
$0.00Board Justification
No bonus was awarded to Stanley C. Erck for 2023 due to his retirement.
Other Compensation
$3.83MBoard Justification
Other compensation includes consulting fees and accrued but unused paid time off payable upon retirement.
Restricted Stock
Board Justification
The vested stock represents restricted stock units (RSUs) that vested in 2023.
Performance Metrics
The performance metrics for 2023 included company revenue and strategic goals related to product delivery and financial strength.
Stanley C. Erck
CEO of Novavax
Sector of Economy
Healthcare
CEO of Novavax for
14 years 7 months (Apr 2011 - Present)
Previous Experience
President, Chief Executive Officer and Director of Iomai Corporation
Other Novavax CEOs
Holdings
Track Stanley C. Erck's stock holdings and portfolio value over time.
Total Stock Sold
$51.02M
$50.83M
312,407.91 NVAX shares
$189.39K
47,689 MXCT shares
What if they kept their stock?
If Stanley C. Erck didn't sell their stock, today they would have:
Extra NVAX312,407.91 shares worth $2.14M and MXCT47,689 shares worth $75.59K.
This is -95.67% and $48.81M less than what they got when they sold the stock.
Insider Trading
Stanley C. Erck's recent stock transactions, purchases, and sales filed with the SEC.
$192.43K
MXCT at $4.04/share
Sep 3, 2024
Sale
21,367 shares
MXCT
Jun 11, 2024
Received
$7.52M
NVAX at $175.55/share
Oct 4, 2021
Sale
$8.66M
NVAX at $176.63/share
Oct 1, 2021
Sale
$22.58M
NVAX at $214.68/share
Jul 1, 2021
Sale
$4.73M
NVAX at $90.33/share
Nov 16, 2020
Sale
$1.37M
NVAX at $111.71/share
Sep 30, 2020
Sale
$3.23M
NVAX at $110.91/share
Sep 28, 2020
Sale
$164.62K
NVAX at $1.65/share
May 14, 2018
Purchase
$113.05K
NVAX at $1.13/share
Nov 9, 2017
Purchase
Rivals
Compare Stanley C. Erck with competitor CEOs and industry peers.
Albert Bourla
CEO of Pfizer
2024 Compensation
Stock
$0.00
Salary
$1.80M
Bonus
$7.02M
Other
$996.06K
Total Holdings
$18.14M
Joaquin Duato
CEO of Johnson & Johnson
2024 Compensation
Stock
$7.13M
Salary
$1.60M
Bonus
$3.22M
Other
$1.08M
Total Holdings
$1.09M
Stéphane Bancel
CEO of Moderna
2023 Compensation
Stock
$0.00
Salary
$1.58M
Bonus
$1.91M
Other
$1.07M
Total Holdings
$335.71M